CDK9 inhibition is currently being evaluated in pre-clinical and clinical studies for the treatment of a number of different cancers, mainly in combination with other chemotherapeutic agents (Hofmeister et al., 2014; Karp et al., 2010). Here, CDK9 is linked to cancer.